New method reveals how well cancer drugs hit their targets

July 12, 2018, The Francis Crick Institute
New method reveals how well cancer drugs hit their targets
Imaging individual cancer cells in a tumor in vivo. Credit: Erik Sahai

Scientists have developed a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumour in real time, revealing which cells interact with the drug and which cells the drug fails to reach.

In the future, the findings, published in Nature Communications, could help clinicians decide the best course and delivery of treatment for cancer patients.

Failure of chemotherapy to reach all cancer cells in a is a major cause of poor treatment outcomes. To study this problem in detail requires a for accurately measuring how well drugs bind their targets—so-called 'drug-target engagement' - in the body.

Existing techniques can't show which cells have been targeted by cancer drugs. This is because measurements are taken from liquefied cancer biopsies, so material from different cells gets mixed together.

Researchers at the Francis Crick Institute and Imperial College London have developed a way to measure and visualise drug-target engagement of within in a tumour, using a miniature fluorescent microscope.

Using their technique, they mapped out how the chemotherapy drug doxorubicin (Adriamycin) targeted in living mice. They found significant variation in drug-target engagement between cells within a single tumour, and between different tumours. They also found that drug-target engagement was better when doxorubicin was administered via abdominal injection rather than intravenously—the currently preferred method for doctors treating patients in many clinics.

"Our findings show that in a mouse model delivery of doxorubicin through the blood does not reach all its in the body, which could help explain why this chemotherapy drug is only partially effective in some cancer patients. In contrast, delivering the drug directly into the abdomen adjacent to ovarian tumours improved its target engagement, but this was still not sufficient to kill the cancer cells" says Erik Sahai, senior author of the paper and Group Leader at the Francis Crick Institute.

"If we know that a specific cancer drug isn't reaching all of the cells within a tumour, it might be that we need to find ways to improve drug delivery throughout the whole tumour. Conversely, if we know the drug does engage its target but is still not sufficiently effective, it might be that different drugs or drug combinations should be explored."

How it works

The technique works by imaging the interaction between two light-sensitive molecules. In this study, the team labelled the DNA inside cancer cells with green fluorescent protein (GFP), which can transfer energy to doxorubicin—which is intrinsically light-sensitive—when it is sufficiently close by. Calculating the efficiency of this energy transfer was used to determine the binding between the drug and DNA of different in real-time.

The team are confident that they can adapt their technique to work with other chemotherapy drugs, and in combination with engineered biosensors that fluorescently tag , so that they can measure -target engagement in various preclinical scenarios.

Explore further: Focussed ultrasound used to improve effects of cancer drugs

More information: Hugh Sparks et al, Heterogeneity in tumor chromatin-doxorubicin binding revealed by in vivo fluorescence lifetime imaging confocal endomicroscopy, Nature Communications (2018). DOI: 10.1038/s41467-018-04820-6

Related Stories

Focussed ultrasound used to improve effects of cancer drugs

July 10, 2018
Researchers have made a breakthrough in more precisely targeting drugs to cancers. Using ultrasound and lipid drug carriers (liposomes), a multi-disciplinary team of biomedical engineers, oncologists, radiologists and anaesthetists ...

Antifungal drug eliminates sleeping bowel cancer cells in mice

May 31, 2018
An antifungal medication, commonly prescribed for toenail infections, could help eliminate dormant cells within bowel tumours, according to new research funded by Cancer Research UK and published in the Journal of Experimental ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

A major step towards individualized cancer therapy

June 4, 2018
Fuyuhiko Tamanoi of Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS) and colleagues in the U.S. succeeded in establishing a powerful and convenient model to analyse human cancer.

New nanotechnology application for difficult-to-treat cancers

May 10, 2017
A new treatment combining shock waves with nanoparticles can successfully treat tumours that are difficult to target using conventional chemotherapy. This is the first time this combined therapy has been tested in live animals. ...

Two drugs are better than one in fight against leukaemia

March 8, 2018
Adelaide scientists have devised a way to enhance the effectiveness of a patient's leukaemia treatment by using a combination of drugs.

Recommended for you

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

Overcoming resistance to a standard chemotherapy drug

July 19, 2018
Despite being studied for decades, the chemotherapy drug cisplatin is revealing new aspects of how it works. Researchers at Winship Cancer Institute of Emory University have identified an enzyme responsible for making tumors ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.